Cryosite (ASX:CTE) Operating Margin %: 19.07% (As of Dec. 2025) — 63% Above Median


ASX:CTE Cryosite Ltd ASX:CTE
51 GF Score
Price A$1.15
GF Value A$0.94
Valuation Modestly Overvalued
View Full Analysis

What is Cryosite Operating Margin %?

Cryosite ASX:CTE +8.49% 51 Operating Margin % is 19.07% as of Dec. 2025, which is 63% above its 10-year median of 11.68. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 204 Medical Diagnostics & Research companies, Cryosite ranks better than 85.78% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cryosite's Operating Income for the six months ended in Dec. 2025 was A$1.58 Mil. Cryosite's Revenue for the six months ended in Dec. 2025 was A$8.27 Mil. Therefore, Cryosite's Operating Margin % for the quarter that ended in Dec. 2025 was 19.07%.

Good Sign:

Cryosite Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Cryosite's Operating Margin % or its related term are showing as below:

ASX:CTE' s Operating Margin % Range Over the Past 10 Years
Min: -8.58   Med: 11.68   Max: 18.84
Current: 18.84


ASX:CTE's Operating Margin % is ranked better than
85.78% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195 vs ASX:CTE: 18.84

Cryosite's 5-Year Average Operating Margin % Growth Rate was 2.20% per year.

Cryosite's Operating Income for the six months ended in Dec. 2025 was A$1.58 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.97 Mil.


Cryosite  (ASX:CTE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cryosite Operating Margin % Related Terms


Cryosite Operating Margin % Historical Data

* Premium members only.

The historical data trend for Cryosite's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Operating Margin % Chart

Cryosite Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.59 16.09 12.77 16.29 17.68

Cryosite Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.59 18.04 16.67 18.58 19.07

ASX:CTE vs TMO, DHR, IDXX: Operating Margin % Comparison

For the Diagnostics & Research subindustry, Cryosite's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cryosite's Operating Margin % falls into.


ASX:CTE
51GF Score
Cryosite Ltd ASX:CTE
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cryosite's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=2.496 / 14.116
=17.68 %

Cryosite's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=1.578 / 8.273
=19.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 19.07% mean?
Cryosite (ASX:CTE) has a Operating Margin % of 19.07% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Cryosite and its competitors. This is 63% above median its historical median of 11.68. According to the industry distribution chart, Cryosite ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 14.2%.
Is Cryosite's Operating Margin % too high?
Cryosite's current Operating Margin % of 19.07% is 63% above median its 10-year median of 11.68. Based on the distribution chart, Cryosite ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #29 out of 204 companies for Operating Margin %. This places Cryosite in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cryosite and its competitors. Cryosite's current Operating Margin % is 19.07%, which is 63% above median its own 10-year median of 11.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Operating Margin % is 19.07%, which is 63% above median its 10-year median of 11.68. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Operating Margin % is 19.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94. GuruFocus considers Cryosite to be Modestly Overvalued.

Key valuation signals for ASX:CTE:

  • Operating Margin %: 19.07% (63% above median its 10-year median of 11.68)
  • GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
  • GF Score™: 51/100

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score

Get the complete analysis for ASX:CTE

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.15
Price
A$0.94
GF Value